Keyphrases
Implant Therapy
100%
Pharmacokinetic Evaluation
100%
Antiretroviral Therapy
100%
Levonorgestrel Implant
100%
Non-nucleoside Reverse Transcriptase Inhibitor (NNRTI)
72%
HIV Patients
63%
Levonorgestrel
45%
Progestin
45%
Subdermal
27%
Nevirapine
27%
Efavirenz
27%
Subdermal Implant
18%
Concomitant Use
18%
Unintended Pregnancy
18%
Pharmacokinetics
18%
Long-acting Reversible Contraception
9%
Family Planning Services
9%
Essential Drugs
9%
Intended Use
9%
Ugandan
9%
Interaction Data
9%
Safe Duration
9%
Duration of Use
9%
Pharmacokinetic Drug Interactions
9%
Economic Status
9%
Pharmacokinetic Model
9%
Health Status
9%
Inappropriate Use
9%
Evidence-based
9%
Mother-to-child HIV Transmission
9%
Hormonal Contraception
9%
Healthcare Professionals
9%
LMIC
9%
Reproductive Health
9%
Negative Interaction
9%
Antiretroviral
9%
Medical Knowledge
9%
Gaps in Knowledge
9%
Maternal Mortality
9%
Gaining Access
9%
Low-middle Income Countries
9%
Sampling Strategy
9%
Child Mortality
9%
Pharmacokinetic Study
9%
Drug Interactions
9%
Public Health Importance
9%
Specific Intent
9%
Oral Contraceptives
9%
Life-saving Interventions
9%
Medicine and Dentistry
Antiretroviral Therapy
100%
Pharmacokinetics
100%
Implant
100%
Levonorgestrel
100%
Human Immunodeficiency Virus
72%
Nonnucleoside Reverse Transcriptase Inhibitor
72%
Gestagen
45%
Nevirapine
27%
Efavirenz
27%
Subdermal Implant
18%
Drug Interaction
18%
Low and Middle Income Countries
18%
Contraceptive Agent
9%
Childhood Mortality
9%
Long-Acting Reversible Contraception
9%
Maternal Mortality
9%
Reproductive Public Health
9%
Arm
9%
Public Health
9%
Family Planning
9%
Drug Therapy
9%
Pharmacology, Toxicology and Pharmaceutical Science
Implant
100%
Levonorgestrel
100%
Pharmacokinetics
100%
HIV
88%
Nonnucleoside Reverse Transcriptase Inhibitor
88%
Progestin
55%
Efavirenz
33%
Nevirapine
33%
Drug Interaction
22%
Maternal Mortality
11%
Childhood Mortality
11%
Contraceptive Agent
11%